Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;2020(171):107-133.
doi: 10.1002/cad.20353. Epub 2020 Jul 12.

The Pharmacogenetics of Efavirenz Metabolism in Children: The Potential Genetic and Medical Contributions to Child Development in the Context of Long-Term ARV Treatment

Mei Tan  1 , Megan Bowers  2 , Phil Thuma  3 , Elena L Grigorenko  4
Affiliations
Review

The Pharmacogenetics of Efavirenz Metabolism in Children: The Potential Genetic and Medical Contributions to Child Development in the Context of Long-Term ARV Treatment

Mei Tan et al. New Dir Child Adolesc Dev. 2020 May.

Abstract

Efavirenz (EFV) is a well-known, effective anti-retroviral drug long used in first-line treatment for children and adults with HIV and HIV/AIDS. Due to its narrow window of effective concentrations, between 1 and 4 μg/mL, and neurological side effects at supratherapeutic levels, several investigations into the pharmacokinetics of the drug and its genetic underpinnings have been carried out, primarily with adult samples. A number of studies, however, have examined the genetic influences on the metabolism of EFV in children. Their primary goal has been to shed light on issues of appropriate pediatric dosing, as well as the manifestation of neurotoxic effects of EFV in some children. Although EFV is currently being phased out of use for the treatment of both adults and children, we share this line of research to highlight an important aspect of medical treatment that is relevant to understanding the development of children diagnosed with HIV.

PubMed Disclaimer

References

    1. AIDSFree. (2018). Summary table of HIV treatment regimens. Arlington, VA: AIDSFree Project.
    1. Apostolova N, Blas-Garcia A, Galindo MJ, & Esplugues JV (2017). Efavirenz: What is known about the cellular mechanisms responsible for its adverse effects. European journal of pharmacology, 812, 163–173. - PubMed
    1. Arendt G, de Nocker D, von Giesen H-J, & Nolting T (2007). Neuropsychiatric side effects of efavirenz therapy. Expert Opinion on drug safety, 6(2), 147–154. - PubMed
    1. Ariyoshi N, Miyazaki M, Toide K, Sawamura Y. i., & Kamataki T (2001). A Single Nucleotide Polymorphism of CYP2B6 Found in Japanese Enhances Catalytic Activity by Autoactivation. Biochemical and Biophysical Research Communications, 281(5), 1256–1260. doi: 10.1006/bbrc.2001.4524 - DOI - PubMed
    1. ARROW Trial Team. (2013). Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. The Lancet, 381(9875), 1391–1403. - PMC - PubMed

MeSH terms